Perceived medication assignment during a placebo-controlled laboratory study of varenicline: Temporal associations of treatment expectancies with smoking-related outcomes

Psychopharmacology

Volumn 231, Issue 13, 2014, Pages 2559-2566

  Correa, John B ^a   Heckman, Bryan W ^a   Marquinez, Nicole S ^a   Drobes, David J ^a,b   Unrod, Marina ^a,b   Roetzheim, Richard G ^a,b   Brandon, Thomas H ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Expectancies; Smoking behavior; Treatment guess; Varenicline

Indexed keywords

PLACEBO; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

ADULT; ARTICLE; ATTITUDE TO HEALTH; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MODIFIED CIGARETTE EVALUATION QUESTIONNAIRE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PLACEBO EFFECT; PRIORITY JOURNAL; QUESTIONNAIRE; QUESTIONNAIRE OF SMOKING URGES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REINFORCEMENT; REWARD; SELF REPORT; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SMOKING HABIT; TOBACCO DEPENDENCE; TREATMENT EXPECTATION; WITHDRAWAL SYNDROME; ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG THERAPY; MIDDLE AGED; PERCEPTION; PROCEDURES; PROSPECTIVE STUDY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SMOKING; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; BENZAZEPINES; CUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; PERCEPTION; PLACEBO EFFECT; PROSPECTIVE STUDIES; QUINOXALINES; REINFORCEMENT (PSYCHOLOGY); REWARD; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84903317214     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3420-2     Document Type: Article

References (39)

1. Bailey SR, Fong DM, Bryson W, Fortmann SP, Killen JD (2010) Perceived drug assignment and treatment outcome in smokers given nicotine patch therapy. J Subst Abuse Treat 39:150-156
2. Benedetti F (2008) Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 48: 33-60
3. Biener L, Abrams DB (1991) The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol 10:360-365
4. Brandon TH, Drobes DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim RC, Karver SB, Small BJ (2011) Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacol 218:391-403
5. Buchanan TS, Sanderson Cox L, Thomas JL, Nollen NL, Berg CJ, Mayo MS, Ahluwalia JS (2013) Perceived treatment assignment and smoking cessation in a clinical trial of bupropion versus placebo. Nicotine Tob Res 15:567-571
6. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG (2007) Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav 32: 912-923 (Pubitemid 46282288)
7. Carter BL, Robinson JD, Lam CY, Wetter DW, Tsan JY, Day SX, Cinciripini PM (2006) A psychometric evaluation of cigarette stimuli used in a cue reactivity study. Nicotine Tob Res 8:361-369 (Pubitemid 43977038)
8. Center for the Study of Emotion and Attention (1995) The International Affective Picture System [photographic slides]. The Center for Research in Psychophysiology. University of Florida, Gainesville
9. Dar R, Stronguin F, Etter JF (2005) Assigned versus perceived placebo effects in nicotine replacement therapy for smoking reduction in Swiss smokers. J Consult Clin Psychol 73:350-353 (Pubitemid 40446392)
10. Drobes DJ (2002) Cue reactivity in alcohol and tobacco dependence. Alcohol Clin Exp Res 26:1928-1929
11. Etter JF, Schneider NG (2013) An internet survey of use, opinions and preferences for smoking cessation medications: nicotine, varenicline, and bupropion. Nicotine Tob Res 15:59-68
12. Fairbairn CE, Dundon WD, Xie H, Plebani JG, Kampman KM, Lynch KG (2008) Study blinding and correlations between perceived group assignment and outcome in a cocaine pharmacotherapy trial. Am J Addict 17:387-391
13. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F (2010) Biological, clinical, and ethical advances of placebo effects. Lancet 375:686-695
14. First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured Clinical Interview for DSM-IVAxis I Disorders, Clinician Version (SCID-CV). American Psychiatric Press, Inc., Washington
15. Fucito LM, Toll BA, Salovey P, O'Malley SS (2009) Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment. Psychol Addict Behav 23:373-379
16. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47-55
17. Gottlieb AM, Killen JD, Marlatt GA, Taylor CB (1987) Psychological and pharmacological influences in cigarette smoking withdrawal: effects of nicotine gum and expectancy on smoking withdrawal symptoms and relapse. J Consult Clin Psychol 55:606-608
18. Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993) Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4:3-13 (Pubitemid 23062644)
19. Hall SM, Gorecki JA, Reus VI, Humfleet GL, Muñoz RF (2007) Belief about drug assignment and abstinence in treatment of cigarette smoking using Nortriptyline. Nicotine Tob Res 9:467-471 (Pubitemid 46534458)
20. Harrell PT, Juliano LM (2012) A direct test of the influence of nicotine response expectancies on the subjective and cognitive effects of smoking. Exp Clin Psychopharmacol 20:278-286
21. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991) The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 86:1119-1127
22. Hughes JR, Pickens RW, Spring W, Keenan RM (1985) Instructions control whether nicotine will serve as a reinforcer. J Pharmacol Exp Ther 235:106-112 (Pubitemid 15242372)
23. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56-63
24. Juliano LM, Brandon TH (2002) Effects of nicotine dose, instructional set, and outcome expectancies on the subjective effects of smoking in the presence of a stressor. J Abnorm Psychol 111:88-97 (Pubitemid 34150826)
25. Kelemen WL, Kaighobadi F (2007) Expectancy and pharmacology influence the subjective effects of nicotine in a balanced-placebo design. Exp Clin Psychopharmacol 15:93-101
26. Kidorf M, Stitzer ML, Griffiths RR (1995) Evaluating the reinforcement value of clinic-based privileges through amultiple choice procedure. Drug Alcohol Depend 39:167-172
27. Kirsch I (1997) Specifying nonspecifics: psychological mechanisms of placebo effects. In: Harrington A (ed) The placebo effect: an interdisciplinary exploration. Harvard University Press, Cambridge, pp 166-186
28. Margraf J, Ehlers A, Roth WT, Clark DB, Sheikh J, Agras WS, Taylor CB (1991) How "blind" are double-blind studies? J Consult Clin Psychol 59:184-187
29. McKee S, Harrison E, Shi J (2010) Alcohol expectancy increases positive responses to cigarettes in young, escalating smokers. Psychopharmacol 210:355-364
30. Mooney M, White T, Hatsukami D (2004) The blind spot in the nicotine replacement therapy literature: assessment of the double-blind in clinical trials. Addict Behav 29:673-684 (Pubitemid 38591574)
31. Nelder JA, Wedderburn RWM (1972) Generalized linearmodels. J R Stat Soc Ser A 135:370-384
32. Perkins KA, Sayette M, Conklin C, Caggiula A (2003) Placebo effects of tobacco smoking and other nicotine intake. Nicotine Tob Res 5:695-709 (Pubitemid 37304844)
33. Perkins KA, Doyle T, Ciccocioppo M, Conklin C, Sayette M, Caggiula A (2006) Sex differences in the influence of nicotine dose instructions on the reinforcing and self-reported rewarding effects of smoking. Psychopharmacol 184:600-607 (Pubitemid 43255876)
34. Reid MS, Palamar J, Raghavan S, Flammino F (2007) Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacol 192:147-158 (Pubitemid 46673896)
35. Schnoll RA, Epstein L, Audrain J, Niaura R, Hawk L, Shields PG, Lerman C, Wileyto EP (2008) Can the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation. J Subst Abuse Treat 34: 234-241
36. Shiffman S, Ferguson SG, Rohay J, Gitchell JG (2008) Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction 103:1371-1378 (Pubitemid 352009053)
37. Thomas JL, Guo H, Lynam IM, Powell JN, Okuyemi KS, Bronars CA, Ahluwalia JS (2008) The impact of perceived treatment assignment on smoking cessation outcomes among African-American smokers. J Gen Intern Med 23:1361-1366
38. Tiffany ST, Drobes DJ (1991) The development and initial validation of a questionnaire on smoking urges. Br J Addict 86:1467-1476
39. Wray JM, Gass JC, Tiffany ST (2013) A systematic review of the relationships between craving and smoking cessation. Nicotine Tob Res 15:1167-1182